Table 3.
Characteristics |
CA199 level |
P value | |
≤ 25.45 U/mL (n = 57) | > 25.45 U/mL (n = 97) | ||
Age (yr) | |||
≤ 60 | 24 (15.6) | 32 (20.8) | 0.299 |
> 60 | 33 (21.4) | 65 (42.2) | |
Sex | |||
Male | 23 (14.9) | 40 (26.0) | 0.914 |
Female | 34 (21.1) | 57 (37.0) | |
Cholecystolithiasis | |||
Absent | 32 (20.8) | 47 (30.5) | 0.406 |
Present | 25 (16.2) | 50 (32.5) | |
Diabetes | |||
Absent | 45 (29.2) | 71 (46.1) | 0.447 |
Present | 12 (7.8) | 26 (16.9) | |
Jaundice | |||
Absent | 53 (34.4) | 76 (49.4) | 0.022 |
Present | 4 (2.6) | 21 (13.6) | |
Blood groups | |||
A | 19 (12.3) | 24 (15.6) | 0.303 |
B | 21 (13.6) | 35 (22.7) | |
AB | 1 (0.6) | 8 (5.2) | |
O | 16 (10.4) | 30 (19.5) | |
Pathological types | |||
Adenosquamous carcinoma | 0 (0) | 3 (1.9) | 0.299 |
Adenocarcinoma | 57 (37.0) | 93 (60.4) | |
Papillocarcinoma | 0 (0) | 1 (0.6) | |
Degree of differentiation | |||
Poor | 33 (21.4) | 61 (39.6) | 0.069 |
Moderate-well | 24 (15.6) | 36 (23.4) | |
Resection margin status | |||
Negative | 45 (29.2) | 51 (33.1) | 0.001 |
Positive | 12 (7.8) | 46 (29.9) | |
Maximum tumor diameter (cm) | |||
≤ 2.45 | 30 (19.5) | 38 (24.7) | 0.131 |
> 2.45 | 27 (17.5) | 59 (38.3) | |
T stage | |||
Tis-T1a | 7 (4.5) | 3 (1.9) | < 0.001 |
T1b-T2b | 18 (11.7) | 11 (7.1) | |
T3 | 32 (20.8) | 71 (46.1) | |
T4 | 0 (0.0) | 12 (7.8) | |
N stage | |||
N0 | 43 (27.9) | 55 (35.7) | 0.056 |
N1 | 11 (7.1) | 36 (23.4) | |
N2 | 3 (1.9) | 6 (3.9) | |
Distant metastasis | |||
Absent | 53 (34.4) | 89 (57.8) | 0.783 |
Present | 4 (2.6) | 8 (5.2) | |
TNM stage | |||
0-I stage | 11 (7.1) | 5 (3.2) | < 0.001 |
IIA-IIB stage | 12 (7.8) | 4 (2.6) | |
IIIA-IIIB stage | 27 (17.5) | 65 (42.2) | |
IVA-IVB stage | 7 (4.5) | 23 (14.9) | |
Fibrinogen concentration (g/L) | |||
≤ 3.47 | 37 (24.0) | 38 (24.7) | 0.003 |
> 3.47 | 20 (13.0) | 59 (38.3) |